Schizophrenia Research
Volume 47, Issue 1 , Pages 59-67 , 15 January 2001

Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT

  • Jules Lavalaye

      Affiliations

    • Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands
    • Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • Graduate School of Neurosciences, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Present address: Department of Psychiatry, Academic Medical Center, Tafelbergweg 25, 1105 BC Amsterdam, The Netherlands. Tel.: +31-20-5667268; fax: +31-20-5667072
    • ,
  • Don H. Linszen

      Affiliations

    • Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Jan Booij

      Affiliations

    • Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Peter M.A.J. Dingemans

      Affiliations

    • Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Liesbeth Reneman

      Affiliations

    • Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • Graduate School of Neurosciences, Amsterdam, The Netherlands
    • ,
  • Jan B.A. Habraken

      Affiliations

    • Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Berthold P.R. Gersons

      Affiliations

    • Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Eric A. van Royen

      Affiliations

    • Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands

Received 30 September 1999 ,Accepted 28 January 2000.

References 

  1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry. 1998;155:761–767
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. fourth ed.. Washington, DC: American Psychiatric Press; 1994;
  3. Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 1989;154:672–676
  4. Booij J, Habraken JA, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J. Nucl. Med. 1998;39:1879–1884
  5. Booij J, Hemelaar JM, Speelman JD, de Bruin K, Janssen AM, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J. Nucl. Med. 1999;40:753–761
  6. Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur. J. Nucl. Med. 1997;24:68–71
  7. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA. 1997;94:2569–2574
  8. Chinaglia G, Alvarez FJ, Probst A, Palacios JM. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol. Neuroscience. 1992;49:317–327
  9. Czudek C, Reynolds GP. [3H]GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia. J. Neural Transm. 1989;77(Suppl.):227–230
  10. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry. 1991;148:1474–1486
  11. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J. Neurosci. 1998;18:5901–5907
  12. Habraken JA, Booij J, Slomka P, Busemann Sokole E, van Royen EA. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J. Nucl. Med. 1999;40:1091–1097
  13. Hietala J, Syvälahti E, Vuorio K, Någren K, Lehikoinen P, Ruotsalainen U, et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch. Gen. Psychiatry. 1994;51:116–123
  14. Hietala J, Syvälahti E, Vuorio K, Räkköläinen V, Bergman J, Haaparanta M, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 1995;346:1130–1131
  15. Hietala J, Syvälahti E, Vilkman H, Vuorio K, Räkköläinen V, Bergman J, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr. Res. 1999;35:41–50
  16. Hirai M, Kitamura N, Hashimoto T, Nakai T, Mita T, Shirakawa O, et al. [3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics. Jpn. J. Pharmacol. 1988;47:237–243
  17. Joyce JN, Lexow N, Bird E, Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse. 1988;2:546–557
  18. Kay SR, Fiszbein A, Opler LA. The positive and negative symptom scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  19. Knable MB, Hyde TM, Herman MM, Carter JM, Bigelow L, Kleinman JE. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol. Psychiatry. 1994;36:827–835
  20. Laruelle M, Abi-Dargham A, van Dyck CH-, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA. 1996;93:9235–9240
  21. Laruelle M, Abi-Dargham A, Gil R, Erdos J, D'Souza CD, Zoghbi SS, et al. SPECT measurements of dopamine transporters in schizophrenia. (abst.) J. Nucl. Med. 1996;37:33
  22. Lavalaye, J., Knol, R.J., de Bruin, K., Reneman, L., Janssen, A.G.M., Booij, J. [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. Eur. J. Nucl. Med., 27, 396–399 2000
  23. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 1987;91:415–433
  24. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 1979;134:382–389
  25. Pearce RK, Seeman P, Jellinger K, Tourtellotte WW. Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia. Eur. Neurol. 1990;30(Suppl. 1):9–14
  26. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA. 1994;91:11651–11654
  27. Rivest R, Falardeau P, Di Paolo T. Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res. 1995;692:269–272
  28. Seeman MV. Psychopathology in women and men: focus on female hormones. Am. J. Psychiatry. 1997;154:1641–1647
  29. Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler Chakos M, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am. J. Psychiatry. 1995;152:698–703
  30. Tatsch K, Scherer J, Linke R, Kerner M, Hahn K. Decrease of dopamine transporter binding in neuroleptic-free schizophrenic patients assessed with IPT-SPECT. (abst.) J. Nucl. Med. 1999;40:31
  31. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J. Nucl. Med. 1995;36:1175–1181
  32. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 1995;294:577–583
  33. Volkow ND, Wang GJ, Fowler JS, Ding YS, Gur RC, Gatley J, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann. Neurol. 1998;44:143–147

PII: S0920-9964(00)00023-2

Schizophrenia Research
Volume 47, Issue 1 , Pages 59-67 , 15 January 2001

Article Tools

* Image Usage & Resolution